USPTO serial 79432260
ASTEX PHARMACEUTICALS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 28, 2026
- Examiner
- GOODMAN, WENDY BETH
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ASTEX PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Recorded and downloadable computer software used for drug discovery in the field of drug discovery research and pharmaceutical drug development; recorded and downloadable computer software used for biotechnology research in the field of drug discovery and pharmaceutical drug development; recorded and downloadable computer software used for scientific analysis in the field of drug discovery and pharmaceutical drug development; recorded and downloadable computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for use in drug discovery, biotechnology research and scientific analysis in the field of drug discovery and pharmaceutical drug development; recorded and downloadable computer software applications for use in designing and developing artificial intelligence, information technology, deep learning, machine learning, and reinforcement learning for use in drug discovery, biotechnology research and scientific analysis; recorded and downloadable computer programs and software algorithms for use in manipulating received or inputted data generated in a virtual space for use in connection with artificial intelligence methods, natural language processing, natural language understanding, natural language human-machine interfaces and predictive assistance technologies; recorded computer programs using artificial intelligence, machine learning, deep learning, and reinforcement learning for use in software development in the field of drug discovery, biotechnology research and scientific analysis | ACTIVE | — |
| 042 | Pharmaceutical drug development services; drug discovery services; biotechnology research; scientific research and analysis in the field of drug discovery and pharmaceutical drug development; providing scientific health care research information in the field of pharmaceuticals and clinical trials; research and development in the field of pharmaceuticals | ACTIVE | — |
| 044 | Providing health care information via telephone and the internet; providing information in the field of the diagnostic, prophylactic, and therapeutic properties of pharmaceuticals. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Astex Therapeutics Limited
- Other trademarks owned by Astex Therapeutics Limited
- Other trademarks owned by Astex Therapeutics Limited
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ASTEX PHARMACEUTICALS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 28, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 28, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 9, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 9, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 3, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 11, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 8, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 8, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 8, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 5, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 20, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 20, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 17, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 16, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 5, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 20, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 15, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 15, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 11, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |